Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Hyperglycemia 2Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1

Interventions

Insulin Glargine 4Insulin 3volagidemab 2Metformin 2Fulvestrant 2Alpelisib 2ziprasidone 1relacorilant 1pembrolizumab 1exemestane 1dapagliflozin 1Vildagliptin 1Tamoxifen 1Standard of Care 1Olanzapine 1Letrozole 1Insulin Lispro 1Insulin Aspart 1Injections 1DNA, Ribosomal 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hyperglycemia × volagidemab × Clear all
NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated
1 enrolled
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04253223 2021-06-11

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Duke University

Phase 1 Terminated
1 enrolled
Lymphoid

Hyperglycemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡